Market Analysts see Paratek Pharmaceuticals Inc. [PRTK] gaining to $15. Time to buy?

Paratek Pharmaceuticals Inc. [NASDAQ: PRTK] closed the trading session at $7.96 on 04/09/21. The day’s price range saw the stock hit a low of $6.9399, while the highest price level was $8.46. The company report on April 2, 2021 that Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on March 31, 2021, the Company granted stock options and restricted stock units to three new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company’s board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.The stock options are to acquire, in the aggregate, 1,200 shares of the Company’s common stock at a per share exercise price of $7.06, the closing sales price on March 31, 2021, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service. The restricted stock units are to acquire, in the aggregate, 13,800 shares of the Company’s common stock and shall vest upon the conclusion of a 36-month vesting period, under which one hundred percent 100% of the restricted stock units will vest after 36 months of employment, subject to the employee’s continuous service. The stock options and restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement and restricted stock unit award agreement covering each grant.About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use.The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC, or Almirall. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.In 2019, Paratek was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for the treatment of pulmonary anthrax.For more information, visit www.ParatekPharma.com or follow @ParatekPharma on Twitter.About NUZYRA®NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.Please see full Prescribing Information for NUZYRA at www.NUZYRA.com.CONTACT:Investor and Media Relations: Ben Strain 617-807-6688 ir@ParatekPharma.com.

The stocks have a year to date performance of 27.16 percent and weekly performance of 13.23 percent. The stock has been moved at 39.65 percent over the last six months. The stock has performed -2.45 percent around the most recent 30 days and changed 24.76 percent over the most recent 3-months.

If compared to the average trading volume of 397.76K shares, PRTK reached to a volume of 5218392 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Paratek Pharmaceuticals Inc. [PRTK]:

Jefferies have made an estimate for Paratek Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 02, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $19 to $22. The new note on the price target was released on November 09, 2020, representing the official price target for Paratek Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $6, while WBB Securities analysts kept a Speculative Buy rating on PRTK stock.

The Average True Range (ATR) for Paratek Pharmaceuticals Inc. is set at 0.43, with the Price to Sales ratio for PRTK stock in the period of the last 12 months amounting to 6.95.

PRTK stock trade performance evaluation

Paratek Pharmaceuticals Inc. [PRTK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.23. With this latest performance, PRTK shares dropped by -2.45% in over the last four-week period, additionally plugging by 39.65% over the last 6 months – not to mention a rise of 88.63% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRTK stock in for the last two-week period is set at 62.90, with the RSI for the last a single of trading hit 70.25, and the three-weeks RSI is set at 59.36 for Paratek Pharmaceuticals Inc. [PRTK]. The present Moving Average for the last 50 days of trading for this stock 7.43, while it was recorded at 7.20 for the last single week of trading, and 6.00 for the last 200 days.

Paratek Pharmaceuticals Inc. [PRTK]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Paratek Pharmaceuticals Inc. [PRTK] shares currently have an operating margin of -160.91 and a Gross Margin at +80.33. Paratek Pharmaceuticals Inc.’s Net Margin is presently recorded at -205.74.

Return on Total Capital for PRTK is now -40.30, given the latest momentum, and Return on Invested Capital for the company is -51.77. Additionally, PRTK Total Debt to Total Capital is recorded at 167.92, with Total Debt to Total Assets ending up at 142.56.

Reflecting on the efficiency of the workforce at the company, Paratek Pharmaceuticals Inc. [PRTK] managed to generate an average of -$490,056 per employee. Receivables Turnover for the company is 3.71 with a Total Asset Turnover recorded at a value of 0.22.Paratek Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.20 and a Current Ratio set at 6.90.

Earnings per share (EPS) analysis for Paratek Pharmaceuticals Inc. [PRTK] stock

With the latest financial reports released by the company, Paratek Pharmaceuticals Inc. posted -0.66/share EPS, while the average EPS was predicted by analysts to be reported at -0.8/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRTK.

Paratek Pharmaceuticals Inc. [PRTK]: Insider Ownership positions

There are presently around $190 million, or 54.30% of PRTK stock, in the hands of institutional investors. The top three institutional holders of PRTK stocks are: BLACKROCK INC. with ownership of 3,447,329, which is approximately 13.741% of the company’s market cap and around 6.40% of the total institutional ownership; OMEGA FUND MANAGEMENT, LLC, holding 2,600,410 shares of the stock with an approximate value of $20.7 million in PRTK stocks shares; and VANGUARD GROUP INC, currently with $17.64 million in PRTK stock with ownership of nearly 7.48% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Paratek Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 60 institutional holders increased their position in Paratek Pharmaceuticals Inc. [NASDAQ:PRTK] by around 3,089,016 shares. Additionally, 45 investors decreased positions by around 1,618,803 shares, while 20 investors held positions by with 19,147,208 shares. The mentioned changes placed institutional holdings at 23,855,027 shares, according to the latest SEC report filing. PRTK stock had 25 new institutional investments in for a total of 1,389,887 shares, while 15 institutional investors sold positions of 314,766 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam